Last week, U.S. consumer groups and labour unions petitioned the U.S. Federal Trade Commission to block Novo Holdings, the ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

Citigroup has promoted three senior healthcare investment bankers - Sumit Khedekar, Nishant Jadav and Michael Guarino - in ...

The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief ...

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...

Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...

Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the ...

Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...